janetcanada's Profile
janetcanada's Posts
Good afternoon Paul, please forget my offering a book to you. I notice you do not post on IHUB since and wondering if it is because you do not wish me to send you a book.
It is O.K really and there is no problem. I had this idea to offer to send you a copy to you because you seems to be a very nice person and was a friendly gesture nothing more
Again please forget about
A friendly hug
silvana
From another Board:
May 28, 2009
Media Release - Alberta Council of Technologies
Stem cell research promises to reduce health care costs
ABCTech hosting events in Calgary and Edmonton
EDMONTON, May 27, 2009/ Troy Media/ -- The Alberta Council of Technologies (ABCTech) will be hosting events in both Calgary and Edmonton in June launching a campaign to demystify stem cell therapeutics (SCT).
The Edmonton event, to be held on June 22 at the Alberta Research Centre features presenter - Dr. Martin Ferguson-Pell, Dean of Rehabilitative Medicine at the University of Alberta. The Calgary event, to be held on June 23 at the Alberta Research Centre features presenter -Dr. Sam Weiss, Director of the Hotchkiss Brain Institute at the University of Calgary.
“Both events,” said Dr. Perry Kinkaide, ABCTech president, “are being held to acquaint the public with the extraordinary promise and issues associated with this revolutionary therapy on the future of health care.
“Imagine a future,” he added, “when cells taken from you own body may be used to mend a bone, restore hair and skin, or prevent, reverse or even cure a number of diseases such as Parkinson's and Alzheimer's.”
Alberta, he said, has a solid foundation of credible researchers with a toe-hold in the commercialization of stem cell therapeutics, including Stem Cell Therapeutics Corp. in Calgary “The province has the means,” he said, “to establish itself as a leader in this fast emerging specialty, but cooperation among research and business interests will be essential. Stem cell therapy holds so much promise, especially now that (US President Barack) Obama has promised that research – and that includes stem cell research – will no longer take a backseat to political beliefs, as it did under (former US President George W.) Bush.”
Obama's timing, he added, couldn't be better, especially when the economic impact of the degenerative dysfunction of an aging population consumes 80% of health-care budgets in direct costs and causes four times that in indirect costs due to lost productivity.
“The emerging partnership between bio-science, bio-engineering and business, especially in Alberta” he said, “bodes well for the future of this promising new field of medicine, but are we ready for the changes – among the professions, regulatory clearance for allowing quick access for the public to this significantly new treatment technique?”
Keynote addresses by Drs. Weiss and Ferguson-Pell at the events will be followed by a response panel of ethicists, investors, researchers and public policy and rehabilitation specialists, who will discuss the dramatic implications of stem cell therapy on the treating of degenerative diseases associated with ageing, injury and lifestyle. “We anticipate a lively and insightful discussion about some of the far reaching implications of SCT on health care costs and the ethical issues of extending and enhancing the quality of life,” Kinkaide said.
Both events are being co-hosted by the Alberta Council of Technologies and the Alberta Health Industry Association and are being sponsored by Pfizer Inc. and the Edmonton and Calgary Associations for Advanced Technology.
For more information:
Perry Kinkaide
President
Alberta Council of Technologies
Toll Free 1-866-241-7535
First message Next in thread
The May 20, 2009 AGM was a “good news” AGM
For starters, we’re getting a PR tomorrow morning with the results of the “orphaned” 7 patients that were enrolled in the Phase IIb stroke Trial that was halted. This trial was basically identical to the 12 patient Phase IIa Trial that had such great results, except that this one was a randomized double blind Trial. When it was halted, 7 patients had been enrolled … 2 treated with our hCG + EPO, and the other 5 with a placebo (basically salt water). The 2 treated patients did better than the 12 did in the Phase IIa Trial. This is good. The 5 placebo patients did less well than we had assumed that untreated patients would do. This is good for us statistically. The patient count is way way way too small to give us a free pass to an Approval, but I think that the results are great. More on this tomorrow after we get the PR.
The new “modified EPO” protocol is the just our regular protocol, but with “slightly less” EPO. Because we are now the only company allowed to proceed with EPO (at any level) so far for central nervous system disorders, the exact new protocol is not being disclosed … so that we can keep a competitive edge. Alan Moore said that they expect the new protocol to work as well as the old protocol.
We are still on hold (by Health Canada) for the Traumatic Brain Injury (TBI) Trial, but is expected that this hold will be removed too.
I asked what differences we might expect between a stroke Trial and a TBI Trial under the same protocol. Alan said that we would have to wait for the results as nobody has ever done this before. He was willing to tell us that the rat Trials for stroke (that gave us results that paralleled the human results nicely) were giving essentially the same results to the rat Trials for TBI …. And that the TBI Rats were showing full recovery in 21 days.
While we’re comparing Stroke vs TBI … it was pointed out that our only competitor for stroke is tPA (usually called a clot buster). tPA is designed to break up blockage to the blood flow in the brain, and must be administered within 3 hours of the stroke occurring, at a location set up to do it. It has the nasty side effect of brain hemorrhage. The one brand of tPA on the market was being challenged by Vipromex (spelling?) with a new product, but the Vipromex product failed. The tPA application is available to about 5% of stroke victims. For TBI, there is NO other treatment other than what we are putting into our next TBI Trial.
Q. For stroke, what happens beyond the recovery achieved in our Trials after the first 90 days?
A. We don’t know, but with the rats, they continue to improve. Longer is better.
Q. Can we have the slide show that you’re working from put on the web site?
A. Yes. Chloe will look after that.
The MS Trial will be starting this year, and is being funded by “the Canadian Stem Cell Consortium” (I think I have the name right?)
Free is good because we have about $5.5 million in the bank, and out new 128 patient Phase IIb stroke Trial will cost about $3 million.
Alan spoke of having serious partnering discussions in the last half of this year, and when discussing our portfolio of patents, mentioned the PDGF patents (that are suitable for applications with Parkinson’s disease) are apparently of interest to some other companies that could be interested in purchasing them, or rights to them. It looks like there might be some options to postpone any need for further financing.
We haven’t had much news for the last many months because it’s good to keep the promotion to a minimum when you are in negotiations with the FDA. We’re approved now, so we should be expecting to hear of more promotion (and news) in the future. If anyone here knows of any innovative ways to get the story out, let Alan know. He’s interested.
The CBC had asked us to let them know when the FDA lifted their hold, we told them a few days ago, and they showed up at the AGM with a TV camera. Nothing was said as to how or when the recorded footage would be used.
Their new member on the Science advisory team, Dalton Dietrich (spelling?) has strong ties with the US Dept of Defense, and has a strong interest in TBI.
Stroke Trial enrollment is to start early in Q3 … think July 1 or a little later. Trials will be run in Canada (2 sites?) and in India (10 sites). The Trial will be completed before the end of this year. Although double blinded, the “Data Safety Monitoring Board” is not blinded, so we have the possibility of both enrollment and safety updates as the Trial progresses.
Insiders own somewhere between 10% and 13% of SCT, and these are shares that were bought at higher prices than we’ve been able to get over the last several months.
Alan said that he was not being allowed to include the slide in his presentation any more that showed a fair share price evaluation as being over $5.00 per share. He didn’t hesitate to let us know though that everything that had justified that figure still stands (now that the Trials can start again).
There is more, but I’ll have to re-read my notes a few times to figure out what I’ve forgotten.
Sorry for the scrambled nature of this post, but I’m smiling too much to keep this post well organized.
It was a very good AGM.
rjc
LYNN MOORE
The Gazette
Friday, November 28, 2008
Unconventionalnatural gas reserves
in the St. Lawrence Lowlands could generate morejobs and economic benefits for the province than Hydro-Québec does, aformer president of the provincial utility told an equally enthusiasticgathering at Quebec Exploration 2008 yesterday.
The projectedfigures for the Utica shale gas play "are so big," Hydro-Québec'salmost pale in comparison, said André Caillé, the onetime Hydro boss.Caillé, also a former CEO of Gaz Métropolitain, now is a senior adviserfor Junex, one of the junior companies with extensive holdings in thelowlands.
"The Utica shale (gas) is something that could be very very significant for Quebec, economically and socially," he said.
Gaswells in those fields could generate 10,000 direct jobs and $10 billionin economic spinoffs, Caillé said Wednesday at the annual dinner of theCIM Petroleum Society's Quebec branch.
The multibillion-dollarquestion is not whether there is gas in the lowlands - a broad swathof territory that runs between Montreal and Quebec City - but whetherit can be retrieved economically, Caillé and others said during thefour-day conference, which wrapped up yesterday.
U.S.-ledadvances in technology and horizontal drilling techniques make iteasier and more profitable for producers to exploit shale formations,but costly testing is still needed in Quebec, said Michael Binnion, anexecutive with Calgary-based Questerre Energy. "High risk, high reward"defines the St. Lawrence Lowlands play, Binnion said during theconference.
A recent report from Calgary-based Triston Capitalsaid it believes the lowlands could contain as much as 40 trillioncubic feet of recoverable gas, making it one of the largestunconventional gas plays in Canada. But the project is still in itsinfancy and technical challenges remain, the report said.
Therule of thumb is one trillion cubic feet of gas is worth $6 billion -if you can pump it out, said Raymond Savoie, president of Gastem,another Quebec-based junior with extensive land holdings in the region.
Major producers Talisman Energy and Forest Oil have bought into the play and are involved in field work.
Thisweek, Canbriam Energy of Calgary paid $3.5 million to Quebec-basedPetrolympic Ltd. and its joint venture partner Ressources et ÉnergieSquatex Inc. for an interest in their land holdings, which includepositions in the lowlands.
lmoore@thegazette.canwest.com
I agree that the common goal should be to make pertinent informations available for all to benefict. This should be done in a collective altruistic effort. The more informations made publics the better . Differents board have differents peoples reading it and each board can bring new investors
Please escuse my English
Have a nice weekend
janet
IMO, when an information is available on a public board, whether you have to pay to get it or not , it become public!!! If a paying member after reading decide to make it public on another board, this should be is right. He paid for !!!!
Have a very nice day
janet